Atlas Trials

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Clinical trial NCT01388647 · TERMINATED

Trial details

NCT number
NCT01388647
Sponsor
Vector Oncology
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HER-2 Positive Breast Cancer
Start date
2011-08-01
Primary completion
2014-06-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.